Fresenius SE & Co KGaA (FRA:FRE) Given a €52.00 Price Target by HSBC Analysts

Fresenius SE & Co KGaA (FRA:FRE) received a €52.00 ($60.47) price target from stock analysts at HSBC in a research report issued to clients and investors on Thursday, Borsen Zeitung reports. The firm presently has a “neutral” rating on the stock. HSBC’s price target suggests a potential upside of 16.68% from the stock’s current price.

A number of other research firms have also recently commented on FRE. DZ Bank reissued a “buy” rating on shares of Fresenius SE & Co KGaA in a report on Wednesday, July 31st. Jefferies Financial Group set a €43.00 ($50.00) price target on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. set a €58.40 ($67.91) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Thursday. Morgan Stanley set a €50.00 ($58.14) price target on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Monday, September 30th. Finally, Deutsche Bank set a €65.00 ($75.58) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Wednesday, July 31st. Nine research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Fresenius SE & Co KGaA currently has an average rating of “Buy” and an average price target of €57.98 ($67.42).

Shares of Fresenius SE & Co KGaA stock traded up €0.24 ($0.28) during trading on Thursday, reaching €44.57 ($51.82). 1,351,280 shares of the company’s stock were exchanged. Fresenius SE & Co KGaA has a 1-year low of €60.16 ($69.95) and a 1-year high of €80.00 ($93.02). The firm’s 50-day moving average price is €43.63 and its 200 day moving average price is €46.52.

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Read More: How are the companies in the S&P 500 selected?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.